
About
Franck Galland joined the team in 2024 Innate Immunity at Mucosal Sites (Dr. A. Broggi, CIML), where he studies the metabolic role of intestinal epithelial cells in chronic inflammatory bowel diseases (IBD) as well as the therapeutic potential of targeting CoA metabolism.
In 1996, alongside Prof. Philippe Naquet at CIML, he co-discovered the Vanin family of enzymes and subsequently demonstrated the key role of pantetheinase Vnn1 in protecting the intestinal mucosa, stimulating mucus production and strengthening resistance to colitis via regulation of vitamin B5/CoA metabolism.
A professor at Aix-Marseille University (AMU), he has supervised seven doctoral theses. He was the project leader for the creation of the Master of Immunology in 2018, which he still directs today. This Master obtained the label of excellence in 2024 amideX PLUS as part of the initiative TIGER–France 2030.